



ISODIOL INTERNATIONAL INC. INCREASES SIZE OF NON-BROKERED OFFERING AND RETAINS CLARUS SECURITIES AS FINANCIAL ADVISOR

ISODIOL INCREASES SIZE OF PRIVATE PLACEMENT TO \$18 MILLION WITH THE UPSIZE LED BY ANSON FUNDS

May 4, 2018 - Vancouver, BC – [Isodiol International Inc.](#) (CSE: [ISOL](#)) (OTC: [ISOLF](#)) (FSE: [LB6A.F](#)) (the “Company” or “Isodiol”), a global CBD innovator specializing in the development of pharmaceutical, health, and wellness products and now supporting the pharmaceutical industry at large with its recently approved CBD as an Active Pharmaceutical Ingredient, is pleased to announce that it will be increasing the size of its previously announced private placement from \$10,000,000 to \$18,000,000 (the “Private Placement” or the “Offering”). The Company has also engaged Clarus Securities Inc. as financial advisor in connection with the Offering.

The additional investment will be led by Anson Funds, a privately held alternative asset manager. The proceeds from the Offering will be used to fund the recently announced global expansion into China and the UK. The Offering is subject to customary closing conditions and is expected to close on or about May 11th, 2018.

For more information on Isodiol, please visit www.isodiol.com

About Isodiol International Inc.

[Isodiol International Inc.](#) is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products and most recently received approval as having the first CBD



designated as an Active Pharmaceutical Ingredient as was announced [April 26, 2018](#).

Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.

Join Us On Facebook: <https://www.facebook.com/isodiol/>

Twitter: [@isodiol](#)

ON BEHALF OF THE BOARD

Marcos Agramont, CEO & Director

INVESTOR RELATIONS:

Ir@isodiol.com

www.isodiol.com

Forward-Looking Information: *This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company's business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.*

The CSE has not reviewed, approved or disapproved the content of this press release.

